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Introduction
The EuroSIDA observational cohort study was initiated in
1993 by Jens Lundgren (Copenhagen HIV Programme)
and Andrew Phillips (University College London) as the
successor of the AIDS in Europe Study, with the main
objective of assessing the impact of antiretroviral drugs on
outcomes for the general population of HIV-infected
patients living in Europe. As of April 2014 EuroSIDA
included 18,786 patients followed at 111 hospitals in 34
European countries plus Argentina and Israel. Since its
inception, EuroSIDA has provided data published in 202
papers in peer-reviewed journals, among them 14 papers
on hepatitis C virus (HCV) co-infection [1-14] .
As the HIV epidemic has evolved and the incidence of
AIDS has decreased, the focus of EuroSIDA has shifted to
addressing the research questions most pertinent to the
clinical care of Europeans living with HIV on a long-term
basis. With more than a quarter of all EuroSIDA patients
positive for antibodies to HCV, and with growing concern
about the burden of liver-related disease and death, hepati-
tis C research has come to play an increasingly important
role in EuroSIDA in recent years.
This article will describe key characteristics of the
HIV/HCV co-infected population in EuroSIDA, and
summarize the most important EuroSIDA co-infection
studies.
Study design of EuroSIDA
Patients eligible for enrolment in EuroSIDA are HIV-1
infected individuals aged 16 and older. To ensure that
included patients are representative for patients followed
at the participating clinics, EuroSIDA has, enrolled a
new cohort of around 1200-2500 randomly selected
patients every second year. EuroSIDA is the only cohort
of HIV-infected individuals that include patients from
all European geographical regions including the Russian
Federation and other countries of the former Soviet
Union (Figure 1). Comparisons of regional differences in
clinical outcomes are therefore important to most Euro-
SIDA studies.
Extensive demographic and clinical data are collected
at the date of enrolment and prospectively at six-month
intervals from all EuroSIDA patients at clinical sites.
These data are sent to the coordinating center at CHIP, a
WHO Collaborating Centre based at the Department of
Infectious Diseases and Rheumatology at Rigshospitalet,
in Copenhagen, Denmark. Complete information about
the data items collected is available at www.cphiv.dk.
Data have been collected on HCV antibody and HCV-
RNA status since 1997 and on HCV genotype since
2005. Routine liver biochemistry has been collected
since 1999. Information on hepatic encephalopathy,
hepatocellular carcinoma and other manifestations of
decompensated liver disease has been collected since
1998, 2001 and 2010, respectively. Data on liver biopsy
and Fibroscan® have been collected since 2010, with
sites requested to list all previous tests and return the
histological report for internal validation. The META-
VIR classification system is used for determining the
liver fibrosis stage.
One of the major strengths of EuroSIDA is the estab-
lishment of an extensive quality assurance system that
includes data checking at the coordinating office, as well
as regular monitoring visits with source verification of
all new major clinical events, plus a random selection of
individuals followed at the clinics. Detailed information
on the cause of death are collected using the “Coding of
Death in HIV” (CoDe) system [15].
The central plasma repository, which was set up in
1997, receives plasma from most EuroSIDA patients at
six-month intervals. In 2006, all patients with unknown
hepatitis B and C status and stored plasma samples were
identified and tested in a central reference laboratory for
anti-HCV antibodies, HCV-RNA and genotype, as well as
for relevant hepatitis B and D markers. This has estab-
lished a cohort of almost 2,000 HCV antibody-positive
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patients who are well characterized with regards to HCV-
RNA and genotype. The plasma repository has also been
used to test all HCV antibody positive and hepatitis B
surface antigen positive patients for plasma hyaluronic
acid, a marker of liver fibrosis.
Epidemiology of HIV/HCV co-infection in
EuroSIDA
Among the 18,786 HIV-positive individuals enrolled in
EuroSIDA, 16,371 have been tested for HCV antibodies
and 5,298 patients (32.4% (95% CI 31.6 - 33.1)) are
known to be positive. Of those, 3,645 (68.8%) have been
tested for HCV-RNA and 2,571 (70.5% (95% CI 69.1 –
72.0)) were positive for it.
In 2008, the epidemiological and virological character-
istics of 1,940 HCV antibody-positive EuroSIDA patients
were published [14]. These patients had been tested
centrally for HCV-RNA and genotype. The cohort
included 1,496 patients (77%) who tested positive for
HCV-RNA. Among these patients, 786 people (53%)
were infected with genotype 1, while 4%, 29% and 15%
were infected with genotypes 2, 3 and 4, respectively.
Patients who had cleared HCV-RNA spontaneously
were more likely to be female and infected with hepatitis
B virus, whereas people who inject drugs (PWID) were
less likely to have cleared HCV-RNA.
Table 1 describes the characteristics of the 3,030 HCV
antibody-positive patients currently under follow-up in
the clinics who continue to contribute data to Euro-
SIDA. The prevalence of HCV antibody-positivity varies
across different geographic regions. In Eastern and
Southern Europe, where HIV is often acquired through
injecting drug use (IDU), 58% and 29% of patients are
also HCV antibody positive, respectively. In Northern
and Western Europe, where sexual transmission among
men who have sex with men (MSM) is the predominant
mode of HIV transmission, 17% and 20% of patients are
HCV antibody positive, respectively (figure 1). 61% of all
HCV antibody positives have reported IDU as the most
likely mode of HIV transmission, while for 19% and 13%
Anti-HCV antibody prevalence in different EuroSIDA regions 
•  South: 28.8% 
•  West: 20.1%  
•  North: 17.3% 
•  East Central: 34.0% 
•  East: 57.7% 
•  Argentina: 20.6% 
Figure 1 Anti-HCV antibody prevalence in different EuroSIDA regions
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the main risk factor is heterosexual and homosexual
contact, respectively. The median age is 44 years and
two thirds are men. Nearly 85% are receiving combina-
tion antiretroviral therapy (cART) and among them
90.1% have an HIV-RNA below 500 copies/mL. Around
a quarter of all patients have received interferon based
therapy.
Acute hepatitis C and risk of HCV reinfection
Since HCV is more transmissible than HIV through
blood contact, most PWID are already HCV-infected by
the time they are diagnosed with HIV. Sexual transmis-
sion of HCV is less likely, but several outbreaks of acute
hepatitis C (ACH) have been described in HIV-positive
MSM [16,17]. ACH is often asymptomatic or causes
nonspecific symptoms, but suspicion of ACH may be
raised because of elevated liver-enzymes when patients
come for their routine check-ups. Between 2002 and
2010, we have observed 150 EuroSIDA patients who
seroconverted from HCV antibody-negative to HCV anti-
body-positive, indicating the occurrence of acute infection.
Two-thirds of these cases were among MSM while only
16 cases were among PWID. The incidence of ACH
increased over time in all EuroSIDA regions and was,
despite the low total number of cases, highest among
PWID [18].
Table 1 Characteristics of HCV antibody positive patients currently under follow-up in EuroSIDA
HCV RNA Status
Total (N=3030) Negative (N=837) Positive (N=1370) Unknown (N=823) P-value*
Sex
Female 992 (32.8%) 233 (23.5%) 443 (44.7%) 316 (31.9%) 0.1870
Male 2031 (67.2%) 524 (25.8%) 919 (45.2%) 588 (29.0%)
Age
Median (IQR) 44 (36 - 50) 47 (39 - 52) 47 (38 - 51) 39 (34 - 46) <.0001
CD4 Cell Count
Median (IQR) 512 (340 - 712) 572 (413 - 753) 525 (347 - 723) 445 (273 - 640) <.0001
Transmission Risk
MSM 387 (12.8%) 147 (38.0%) 151 (39.0%) 89 (23.0%) <.0001
IDU 1836 (60.7%) 417 (22.7%) 909 (49.5%) 510 (27.8%)
Heterosexual 574 (19.0%) 123 (21.4%) 200 (34.8%) 251 (43.7%)
Other 226 (7.5%) 70 (31.0%) 102 (45.1%) 54 (23.9%)
Race
Non-White 259 (8.6%) 94 (36.3%) 123 (47.5%) 42 (16.2%) <.0001
White 2764 (91.4%) 663 (24.0%) 1239 (44.8%) 862 (31.2%)
Region of EuroSIDA
South 719 (23.8%) 207 (28.8%) 391 (54.4%) 121 (16.8%) <.0001
West C 437 (14.5%) 162 (37.1%) 224 (51.3%) 51 (11.7%)
North 353 (11.7%) 129 (36.5%) 186 (52.7%) 38 (10.8%)
East C 502 (16.6%) 137 (27.3%) 248 (49.4%) 117 (23.3%)
East 926 (30.6%) 108 (11.7%) 282 (30.5%) 536 (57.9%)
Argentina 86 (2.8%) 14 (16.3%) 31 (36.0%) 41 (47.7%)
HBsAg Status
Negative 2719 (89.9%) 681 (25.0%) 1212 (44.6%) 826 (30.4%) 0.0528
Positive 172 (5.7%) 52 (30.2%) 78 (45.3%) 42 (24.4%)
Unknown 132 (4.4%) 24 (18.2%) 72 (54.5%) 36 (27.3%)
Taking cART
No 467 (15.4%) 92 (19.7%) 191 (40.9%) 184 (39.4%) <.0001
Yes 2556 (84.6%) 665 (26.0%) 1171 (45.8%) 720 (28.2%)
HIV RNA Viral Load(Among those taking cART)
<500copies/ml 2302 (90.1%) 645 (28.0%) 1079 (46.9%) 578 (25.1%) <.0001
Interferon Treatment
Previously Exposed 800 (26.5%) 367 (45.9%) 397 (49.6%) 36 (4.5%) <.0001
*P-value from Kruskal-Wallis or Chi-square test
IDU: injecting drug use; MSM: men who have sex with men; HBsAg: hepatitis B surface antigen, cART: combination antiretroviral therapy
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Persons who clear HCV-RNA either spontaneously or
due to HCV treatment are at risk of becoming re-infected
with HCV if they have continuous risk behavior. To
investigate the occurrence of HCV re-infection in Euro-
SIDA patients, we measured HCV-RNA in the latest
available follow-up plasma sample in all patients with
prior spontaneous clearance included in an earlier study
[14]. Thirty-five of 191 eligible patients (18%) had detect-
able HCV-RNA after a median 3.6 years of follow-up
between the first and second HCV-RNA test. Thirty-
three (94%) were PWID and two (6%) were MSM. Risk
factors for having HCV-RNA recurrence were PWID,
younger age and not receiving cART [11].
Mortality-related findings
In the period from 2000 to 2013, around a quarter of all
deaths among HCV treatment naïve co-infected patients
could be attributed to their HCV infection. Other impor-
tant causes of death among co-infected patients are AIDS
(24%), cardiovascular disease (9%), infections (8%) and
cancer (5%). The rate of liver-related death (LRD) peaked
at age 35-45, and was two to four times lower in East and
East Central compared with other EuroSIDA regions.
Both lower CD4 cell count and elevated HIV-RNA were
associated with increased risk of LRD. For example, the
5-year risk of LRD in patients with ≥F2 fibrosis (versus
<F2) increased from 27-fold to 50-fold in patients with a
CD4 cell count ≥200 cells/microliter and <200 cells/
microliter, respectively [19].
A EuroSIDA study from 2005, which included both
anti-HCV positive and HBsAg positive patients, found
an average annual decrease in the rate of LRD of 7%
from 1994 to 2004. The decrease could be explained by
increases in the CD4 cell count after starting cART.
However, in patients with similar CD4 cell counts the
rate of LRD increased by 13% per year of additional
exposure to cART [4]. Ongoing analyses have found a
continuous decrease in LRD since 2004 in HCV treat-
ment naïve patients. The reasons for this development
are currently being explored.
In contrast to HBV infection, where there is evidence of
an association between higher HBV-DNA levels and risk
of liver-related death [20], studies investigating the asso-
ciation between HCV-RNA levels and risk of liver-related
death have produced conflicting results. In general, those
studies have been limited by small sample sizes and low
numbers of clinical events [21,22]. A EuroSIDA study by
Rockstroh et al found no effect of level of HCV-RNA or
genotype on risk of liver-related death (N=86) among
2,709 HCV-RNA positive patients. However, patients who
were HCV antibody-positive and HCV-RNA negative had
a five-fold higher risk of liver-related death compared with
HCV antibody-negative persons. This excess risk of LRD
among patients with resolved HCV infection could partly
be explained by a high prevalence of hepatitis B virus
infection in HCV-RNA negative patients [13].
Plasma hyaluronic acid: a strong predictor of
liver-related clinical events and an important
research tool in EuroSIDA
Historically, liver biopsy has been considered the gold
standard for diagnosis and monitoring of the progres-
sion of fibrosis in patients with chronic viral hepatitis
and other liver diseases. However, the drawbacks of liver
biopsy are its invasiveness, imprecision and cost. Non-
invasive low-cost methods to evaluate liver fibrosis are
therefore needed.
EuroSIDA researchers assessed the reliability of plasma
hyaluronic acid (HA) as a predictor of the risk of liver-
related events (liver-related death and hepatic encephalo-
pathy) in all patients who were positive for either HCV
antibodies or hepatitis B surface antigen (HBsAg) and had
stored plasma samples available [10]. Among 1252
included patients, 84 developed a liver-related event dur-
ing a median of 8.2 years of follow-up. Patients with HA
levels below 75 ng/ml (the normal range) in their first
available plasma sample had a cumulative five-year risk of
experiencing a liver-related event of only 1%, whereas the
risk was 12% and 45% for patient with HA levels between
75-250 ng/ml and >250 ng/ml, respectively (Figure 2).
Furthermore, patients who experienced a liver-related
event and were tested for HA prior to their event had a
median annual increase in HA of 108 ng/ml per year,
whereas HA levels remained stable over time in a random
Figure 2 Kaplan Meier progression to liver-related death or
hepatic encephalopathy according to baseline plasma hyaluronic
acid (HA) level The figure shows the cumulative risk of liver-related
death or development of hepatic encephalopathy for patients divided
into three different groups according to the HA level (ng/ml)
measured in the first available stored plasma sample from each
patient. For patients with HA ≤75 ng/ml (the upper limit of normal)
the 5-year risk was only 1%, while patients with HA>250 ng/ml the risk
was nearly 45%. Among the included patients 67% were anti-HCV
positive, the remaining patients had chronic hepatitis B.
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control group of 172 patients from the same cohort, who
did not develop a liver-related event.
Previous fibrosis marker research in hepatitis C has
mainly been cross-sectional and has lacked relevant clini-
cal end points. The results from EuroSIDA show that
plasma HA may serve as a useful clinical tool for monitor-
ing the progression of liver disease. Furthermore, HA has
also proven to be an important research tool in EuroSIDA
and other large studies, where a good estimate of liver dis-
ease severity is often lacking.
Non-liver-related clinical events: is HCV the
culprit or a marker of risk behavior?
HCV infection has been associated with an increased
risk of chronic kidney disease (CKD) and other non-
liver-related clinical events.[12] However, since most
studies investigating these associations have based the
hepatitis C diagnosis only on HCV antibody status, it is
possible that the excess risk is due to other risk factors
among HCV antibody-positive persons (e.g., injecting
drug use) and not HCV per se. Since a large number of
anti-HCV positive patients in EuroSIDA are well-charac-
terized both in terms of HCV-RNA status and fibrosis,
two studies have been conducted to disentangle the rela-
tive importance of these factors.
In one study the incidence of CKD was compared
across three groups of HIV-positive patients: those who
were HCV antibody negative, those who had resolved
HCV infection (anti-HCV positive and HCV-RNA nega-
tive) and those who were anti-HCV positive/HCV-RNA
positive. CKD was defined as a confirmed (> 3 months
apart) estimated glomerular filtration rate of ≤60 ml/
minute per 1.73 m2 (measured by the Cockcroft-Gault
equation). Whereas there was no difference in incidence
of CKD between the first two groups, patients
with chronic HCV infection had a two-fold increased
incidence of CKD (Incidence Rate Ratio 2.12; 95% CI
1.60 – 2.82; p<0.0001). The incidence of HCV did not
vary by HCV genotype. Different HCV-related nephro-
pathies have been described, but this study was not able
to characterize the type of CKD [9].
Earlier EuroSIDA studies and other observational stu-
dies have found that anti-HCV positive persons more fre-
quently discontinued antiretroviral drugs due to toxicity
or physician choice compared with HCV negative patients
[5,6,23]. Again, this could be due to HCV-related liver dis-
ease (since many antiretroviral drugs are metabolized in
the liver) or due to other factors not directly related to
HCV. A recent EuroSIDA study by Grint et al found that
patients with chronic HCV infection had a 26% higher risk
of antiretroviral drug discontinuation compared with
patients with resolved HCV infection (IRR 1.26; 95% CI
1.06–1.50), but that the effect seems to be explained by
more advanced liver fibrosis (as measured by elevated HA
levels) in patients with chronic infection [3]. The effect of
fibrosis on risk of drug discontinuation was mainly seen
for the protease inhibitors (IRR 1.50; 95% CI 1.08–2.08;
p=0.015) and the NRTIs (IRR 1.44; 95% CI 1.05–2.00;
p=0.022), in particular the older NRTIs zidovudine and
didanosine. Interestingly, among the different causes of
toxicity, gastrointestinal toxicity was most common (35%)
while only 7% was due to hepatotoxicity.
Uptake of HCV treatment in EuroSIDA: are the
right patients being targeted?
Until 2011, the standard of care for HIV/HCV co-
infected patients in need of HCV treatment was weekly
subcutaneous injections of pegylated interferon along
with ribavirin taken orally twice per day for 48 weeks.
This treatment eradicated the virus in about 30% to 70%
of cases depending on the HCV genotype [24,25]. Due
to the cost and the potential for adverse effects, most
guidelines only recommended treatment in patients who
had developed significant liver fibrosis and therefore
were at risk of liver-related complications.
In EuroSIDA a quarter of co-infected patients received
HCV treatment between 1998 and 2010. On average, the
incidence of HCV treatment increased 27% per year
between 1998 and 2007 before falling on average 12%
per year between 2007 and 2010 (figure 3). Patients
residing in southern Europe have been more likely to
receive HCV treatment compared with patients from
other EuroSIDA regions. The decrease in recent years is
probably explained by treatment saturation of the
patients in urgent need of therapy, as well as by patients
and physicians waiting for better treatment options
[2,7]. Among the proportion of co-infected patients with
information on fibrosis available, only one-third of trea-
ted patients had significant fibrosis (METAVIR F2 or
greater), while 22% of untreated patients had significant
fibrosis. Hence many patients with minimal short- to
intermediate-term risk of HCV-related complications
received a costly treatment associated with many
adverse effects, while many patients at risk of complica-
tions of their HCV infection did not receive relevant
treatment [2].
Discussion
The EuroSIDA study follows one of the largest cohorts
of HIV/HCV co-infected patients in the world, and is
the only cohort to include patients from all geographical
regions in Europe. The overall prevalence of HCV sero-
positivity among patients tested in EuroSIDA is 32.4%
with the highest burden of co-infection seen in Eastern
Europe where IDU is the most common mode of HIV
transmission.
The large number of patients, detailed virological and
clinical characterization and long-term follow-up have
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enabled EuroSIDA researchers to describe important
regional differences in treatment and the long-term clin-
ical outcome of HIV/HCV co-infected patients in Eur-
ope, but also to disentangle the relative importance of
viral replication, hepatic fibrosis and other risk factors
for some extra-hepatic conditions, such as chronic kid-
ney disease, seen more commonly in this complex
patient population.
Most co-infected patients in EuroSIDA are already
HCV infected at the time of enrolment into EuroSIDA,
but we have, in agreement with other cohort studies,
documented a high risk of both primary HCV infection
and HCV re-infection among PWID and MSM after
enrolment in EuroSIDA. These findings underline
importance of maintaining focus on preventive measures
to reduce injecting drug use, sharing of contaminated
needles and unprotected sex, but also that clinicians
should maintain a high vigilance to identify patients
with new HCV infection early and provide counseling to
minimize the risk of onwards transmission and consider
the need for HCV treatment.
In the period from 2000 to 2013, around a quarter of
all deaths among HCV treatment naïve co-infected
patients could be attributed to their HCV infection, and
despite the ageing of the population and hence longer
time for liver fibrosis to develop, HCV-related mortality
has decreased in the period. Reasons for this develop-
ment, which could be due to more patients with
advanced liver fibrosis accessing HCV treatment, better
control of the HIV infection or competing risks of death,
especially in Eastern Europe (where the HCV epidemic is
also more recent), are currently being explored.
Striking regional differences in causes of death were
observed, with AIDS and non-liver-related death domi-
nating in Eastern Europe whereas rates of liver-related
death still remained low compared with other European
regions. The same study confirmed that lower CD4 cell
counts, HIV viral replication and HBV co-infection are
all risk factors for liver-related death. These findings
highlight the importance of HIV treatment as part of an
integrated strategy to decrease the burden of not only
HIV-related death, but also HCV-related death among
HIV/HCV co-infected patients.
Until now, HCV treatment is likely to have improved the
overall mortality of co-infected patients in EuroSIDA only
minimally. We have shown that only a quarter of all co-
infected patients in EuroSIDA have ever received inter-
feron-based therapy, and among those who were treated
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Figure 3 Temporal change in Incidence of uptake of HCV treatment among EuroSIDA patients In the period from 1998 -2007 the uptake
of HCV treatment increased on average 27% per year (unadjusted incidence rate ratio: 1.27 (95% CI: 1.23 -1.31). From 2007 – 2010 the uptake of
HCV decreased 12% per year (unadjusted IRR: 0.88 (95% CI: 0.79 -0.98).
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only a third had evidence of significant liver fibrosis. On
the other hand, 22% of all untreated patients have signifi-
cant fibrosis. The reasons for the latter could be lack of
access to or contraindications to therapy or fear of adverse
effects of interferon and ribavirin.
With the recent approval of potent and well-tolerated
oral direct acting antivirals (DAAs) against HCV and
the prospect of interferon-free treatment for all HCV
genotypes, new HCV therapy could potentially eradicate
the virus in nearly all treated patients and sharply
reduce HCV related mortality [26]. However, given the
exorbitant prices of DAAs, it is already clear now that
unless their cost is reduced substantially, DAA-based
therapy will be inaccessible for many HCV infected
patients in many parts of Europe.
Monitoring of these important regional differences in
uptake of DAA-based therapy across Europe, and to
investigate the short- and long-term efficacy and adverse
effects of these new drugs in a “real-life” co-infected
population as compared with the generally healthier
patients selected for clinical trials, will be an important
future research priority for the EuroSIDA study.
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